Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study
F Brosseron, CC Kolbe, F Santarelli… - Alzheimer's & …, 2020 - Wiley Online Library
Alzheimer's & Dementia, 2020•Wiley Online Library
Introduction Multiple immunity biomarkers have been suggested as tracers of
neuroinflammation in neurodegeneration. This study aimed to verify findings in
cerebrospinal fluid (CSF) samples of Alzheimer's disease (AD) and Parkinson's disease
(PD) subjects from the network of the European, Innovative Medicines Initiative–funded
project AETIONOMY. Methods A total of 227 samples from the studies/centres AETIONOMY,
ICEBERG, and IDIBAPS were used to analyse 21 selected immunity biomarkers in CSF …
neuroinflammation in neurodegeneration. This study aimed to verify findings in
cerebrospinal fluid (CSF) samples of Alzheimer's disease (AD) and Parkinson's disease
(PD) subjects from the network of the European, Innovative Medicines Initiative–funded
project AETIONOMY. Methods A total of 227 samples from the studies/centres AETIONOMY,
ICEBERG, and IDIBAPS were used to analyse 21 selected immunity biomarkers in CSF …
Introduction
Multiple immunity biomarkers have been suggested as tracers of neuroinflammation in neurodegeneration. This study aimed to verify findings in cerebrospinal fluid (CSF) samples of Alzheimer's disease (AD) and Parkinson's disease (PD) subjects from the network of the European, Innovative Medicines Initiative–funded project AETIONOMY.
Methods
A total of 227 samples from the studies/centres AETIONOMY, ICEBERG, and IDIBAPS were used to analyse 21 selected immunity biomarkers in CSF. Results were compared to data of an independent cohort of 399 subjects previously published.
Results
Immunity markers were predominantly and reproducibly associated with pathological levels of tau isoforms, but also with amyloid levels, aging, sex, APOE genotype, and center‐specific factors.
Discussion
Immunity biomarker levels in CSF reflect molecular and cellular pathology rather than diagnosis in neurodegenerative disorders. Assay standardization and stratification for age and other covariates could improve the power of such markers in clinical applications or intervention studies targeting immune responses in neurodegeneration.
Wiley Online Library